Cargando…

Genetic and Epigenetic of Medullary Thyroid Cancer

Medullary thyroid carcinoma (MTC) is an infrequent calcitonin-producing neuroendocrine tumor that initiates from the parafollicular C cells of the thyroid gland. Several genetic and epigenetic alterations are collaterally responsible for medullary thyroid carcinogenesis. In this review article, we s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khatami, Fatemeh, Tavangar, Seyed Mohammad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pasteur Institute 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889499/ https://www.ncbi.nlm.nih.gov/pubmed/29126344 http://dx.doi.org/10.22034/ibj.22.3.142

Ejemplares similares

Liquid Biopsy as a Minimally Invasive Source of Thyroid Cancer Genetic and Epigenetic Alterations
por: Khatami, Fatemeh, et al.
Publicado: (2019)

A Review of Driver Genetic Alterations in Thyroid Cancers
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Liquid Biopsy in Thyroid Cancer: New Insight
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Circulating Tumor BRAF Mutation and Personalized Thyroid Cancer Treatment
por: Khatami, Fatemeh, et al.
Publicado: (2017)

Personalized treatment options for thyroid cancer: current perspectives
por: Khatami, Fatemeh, et al.
Publicado: (2019)

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy
por: Khatami, Fatemeh, et al.
Publicado: (2018)

Oncometabolites as biomarkers in thyroid cancer: a systematic review
por: Khatami, Fatemeh, et al.
Publicado: (2019)

Current Diagnostic Status of Pheochromocytomaand Future Perspective: A Mini Review
por: Khatami, Fatemeh, et al.
Publicado: (2017)

Genetic susceptibility to hereditary non-medullary thyroid cancer
por: Kamani, Tina, et al.
Publicado: (2022)

Meta-analysis of promoter methylation in eight tumor-suppressor genes and its association with the risk of thyroid cancer
por: Khatami, Fatemeh, et al.
Publicado: (2017)

Clear Cell Sarcoma: A Case Report and Review of Literature
por: Abdollahi, Alireza, et al.
Publicado: (2018)

Oncometabolites: A new insight for oncology
por: Khatami, Fatemeh, et al.
Publicado: (2019)

Diagnosis of medullary thyroid cancer
por: Marchisotta, Stefania, et al.
Publicado: (2009)

Promoter Methylation of Four Tumor Suppressor Genes in Human Papillary Thyroid Carcinoma
por: Khatami, Fatemeh, et al.
Publicado: (2019)

Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC)
por: Diquigiovanni, Chiara, et al.
Publicado: (2021)

Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer
por: Miasaki, Fabíola Yukiko, et al.
Publicado: (2020)

Treatment of advanced medullary thyroid cancer
por: Smit, Johannes
Publicado: (2013)

An Introduction to Managing Medullary Thyroid Cancer
por: de Groot, Jan Willem, et al.
Publicado: (2006)

Medullary Thyroid Cancer: Updates and Challenges
por: Gild, Matti L, et al.
Publicado: (2023)

The Emerging Role of Succinate Dehyrogenase Genes (SDHx) in Tumorigenesis
por: Nazar, Elham, et al.
Publicado: (2019)

Mixed Medullary-Follicular Carcinoma of the Thyroid
por: Tohidi, Maasumeh, et al.
Publicado: (2013)

Genetic and epigenetic background and protein expression profiles in relation to telomerase activation in medullary thyroid carcinoma
por: Wang, Na, et al.
Publicado: (2016)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012)

Role of vandetanib in the management of medullary thyroid cancer
por: Brassard, Maryse, et al.
Publicado: (2012)

Advanced medullary thyroid cancer: pathophysiology and management
por: Ferreira, Carla Vaz, et al.
Publicado: (2013)

How I treat medullary thyroid cancer
por: Kiesewetter, B., et al.
Publicado: (2021)

Targeted Treatment of Differentiated and Medullary Thyroid Cancer
por: Bales, Shannon R., et al.
Publicado: (2011)

Genetic Alterations in Medullary Thyroid Cancer: Diagnostic and Prognostic Markers
por: A, Taccaliti, et al.
Publicado: (2011)

Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer
por: Hińcza, Kinga, et al.
Publicado: (2019)

Ceruloplasmin Status in Medullary Thyroid Carcinoma
por: RAZAVI, Fatemeh, et al.
Publicado: (2020)

Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
por: Deshpande, Hari, et al.
Publicado: (2011)

Medullary thyroid cancer: molecular factors, management and treatment
por: Pavlidis, Efstathios, et al.
Publicado: (2020)

Hypercalcitoninemia is not Pathognomonic of Medullary Thyroid Carcinoma
por: Toledo, Sergio PA, et al.
Publicado: (2009)

Medullary Thyroid Carcinoma: An Update on Imaging
por: Kushchayev, Sergiy V., et al.
Publicado: (2019)

Significance of RAS Mutations in Thyroid Benign Nodules and Non-Medullary Thyroid Cancer
por: Marotta, Vincenzo, et al.
Publicado: (2021)

Thyroid: Medullary Carcinoma
por: Somnay, Yash R., et al.
Publicado: (2013)

Dyspnea as the First Manifestation of Silent Renal Cell Carcinoma
por: Khorsand-Rahimzadeh, Atieh, et al.
Publicado: (2019)

The Genetic Aspects of Medullary Thyroid Carcinoma: Recognition and Management
por: Williamson, Paula, et al.
Publicado: (1996)

Management of lymph nodes in medullary thyroid carcinoma: A review
por: Shaghaghi, Ali, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7nn79r7bs2scrcspqe946vh6v3